Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Multiple Myeloma × Standard of Care × Clear all

Phase

Phase NA 6 Phase 1 2 Phase 4 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Colorectal Neoplasms 2 Weight Loss 1 Sleep Initiation and Maintenance Disorders 1 Protein Deficiency 1 Prostatic Neoplasms 1 Prolactinoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Malnutrition 1 Kidney Neoplasms 1 Iron Deficiencies 1 Hemostasis 1 Delirium 1 Carcinoma, Renal Cell 1 Anemia 1

Interventions

Lenalidomide 9 Dexamethasone 9 Zoledronic Acid 7 Bortezomib 7 Melphalan 4 ixazomib 3 daratumumab 3 tocilizumab 2 pomalidomide 2 carfilzomib 2 Prednisone 2 Filgrastim 2 Cyclophosphamide 2 Calcium Dobesilate 2 zanubrutinib 1 talquetamab 1 pegylated granulocyte colony-stimulating factor 1 montelukast 1 isatuximab 1 ibrutinib 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 auricularum 1 apixaban 1 Vaccination 1 Thiotepa 1 Thalidomide 1 Tablets 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07094048 2026-01-07

CHUQUL_HO001

CHU de Quebec-Universite Laval

Phase 4 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡